There Are Only 3 Ways To Increase Your IGF-1 (How To Pick The Right One)

Your pituitary gland is not the only way to raise IGF-1, and understanding why that matters changes how you think about every growth hormone compound on the market.

The full chain works like this. Your hypothalamus releases something called GHRH, which stands for growth hormone-releasing hormone, and its job is to signal the pituitary to release growth hormone. That growth hormone travels to the liver, where it gets converted into something called IGF-1, which is insulin-like growth factor 1, the molecule that actually drives most of the effects people associate with growth hormone: tissue repair, fat metabolism, lean mass retention. The system has a built-in off switch. When IGF-1 climbs high enough, your hypothalamus releases something called somatostatin, which pumps the brakes on the whole process. Your body is constantly balancing the gas pedal and the brake.

Every compound people use to raise IGF-1 plugs into this chain at a different point, and that point determines almost everything about how it behaves.

The first category plugs in at the very beginning of the chain. GHRH analogs, which include Tesamorelin, CJC-1295, and Sermorelin, mimic the signal your hypothalamus would naturally send to the pituitary. They tell the pituitary: release more growth hormone. The pituitary does, growth hormone rises, the liver converts it, and IGF-1 climbs. But the feedback loop is fully intact. When IGF-1 gets high enough, somatostatin rises, the pituitary slows down, and the system self-corrects. This is what puts a ceiling on what these compounds can do, and that ceiling is not a flaw in the drug, it is the body doing exactly what it is designed to do.

The clinical data on Tesamorelin is the most detailed example of what this ceiling looks like in practice. In the 2007 Falutz et al. trial published in the New England Journal of Medicine, HIV patients with lipodystrophy receiving Tesamorelin saw IGF-1 levels rise and visceral fat decrease significantly, but those IGF-1 levels were rising within a range consistent with what healthy pituitary signaling would produce. The system amplified output, it did not override it. That is the appropriate use case for GHRH analogs: restoring GH output that has declined due to age, metabolic dysfunction, or suppression, not exceeding what your physiology is built to sustain.

The second category skips the pituitary entirely. Exogenous human growth hormone is injected directly into the bloodstream, which means the liver sees growth hormone regardless of what the hypothalamus or pituitary are doing. IGF-1 can climb past the ceiling your body would set on its own because the signal is not coming from inside the feedback loop. Two studies make this mechanism concrete. Rosenthal et al. in 1986 showed that exogenous growth hormone actively suppresses the pituitary's response to GHRH, meaning the body reads the external GH and treats it as a reason to slow endogenous production. Hashimoto et al. in 2000 confirmed that even a fragment of exogenous GH, specifically the 20K isoform, suppresses the secretion of the body's own 22K growth hormone in normal men.

This is why stacking a GHRH analog on top of pharmaceutical HGH does not add to the effect. The pituitary has already been told, through rising IGF-1 and suppressed endogenous signaling, to stand down. The GHRH analog is sending a message to a door that is closed. You are paying for a signal the body is not reading.

The third category skips everything. IGF-1 LR3 is a modified version of IGF-1 itself, engineered to have a longer half-life than endogenous IGF-1 because it has reduced binding affinity for the proteins that would normally clear it from circulation. When you inject it, you are not stimulating GH, you are not waiting for liver conversion, you are delivering the end product directly. Chapman et al. in 1998 demonstrated that exogenous IGF-1 suppresses growth hormone release through negative feedback on the hypothalamus and pituitary, confirming that IGF-1 LR3 lands downstream of every regulatory step. This is why the effect is stronger and why the risks scale accordingly. Receptors will downregulate with continuous exposure, which is what forces the six to eight week cycle ceiling: push past that and the receptors stop responding and you have elevated circulating IGF-1 with diminishing signal at the tissue level.

The fat loss piece connects all three categories in a way that clears up a lot of confusion. Growth hormone drives fat loss through something called GH-mediated lipolysis, which is the process by which growth hormone directly activates fat cells to release stored triglycerides. The important detail is where this happens most. Visceral fat, the fat stored around the organs in the abdominal cavity, expresses a higher density of growth hormone receptors than subcutaneous fat. That means GH activity preferentially mobilizes visceral stores first. Johannsson et al. in 1997 showed that GH treatment in abdominally obese men reduced abdominal fat mass specifically, while also improving lipoprotein profiles and lowering diastolic blood pressure.

Tesamorelin gets labeled a visceral fat peptide because the clinical trials that supported its FDA approval measured visceral fat as the primary endpoint. But the mechanism driving that reduction is the same GH-receptor mediated lipolysis that any source of elevated growth hormone would produce. Tesamorelin does not have a unique fat-burning property. It raises GH, GH acts on visceral fat preferentially, and the study design happened to measure that outcome. The same process occurs with Sermorelin, CJC-1295, and pharmaceutical HGH. What changes is how high IGF-1 can go and how the feedback loop responds, not where the fat loss comes from.

None of this works without a calorie deficit. Growth hormone accelerates lipolysis, but if caloric intake replaces what is being mobilized, the net change in fat mass is zero. The Moller and Jorgensen 2009 review in Endocrine Reviews lays out the full picture of GH's metabolic effects and is clear that energy balance determines the outcome even when GH-mediated lipolysis is elevated.

The compound is not the decision. The question is where in the chain your output is limited and how far outside your natural ceiling you are trying to go. If the goal is restoring a system that has declined, the first category works with the feedback loop. If the goal is sustained IGF-1 above your natural ceiling, the second category requires bypassing it. If the goal is maximum short-term IGF-1 with the tightest window before receptor desensitization, the third category does that by delivering the endpoint directly. Each one is a different intervention into the same system, and the biology determines which one matches the goal, not the marketing.

---

References

1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357(23):2359-70. DOI: 10.1056/NEJMoa072375
2. Stanley TL, Grinspoon SK. (2015). Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res 25(2):59-65. DOI: 10.1016/j.ghir.2014.12.005
3. Moller N, Jorgensen JO. (2009). Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152-77. DOI: 10.1210/er.2008-0027
4. Hashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka T. (2000). Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men. J Clin Endocrinol Metab 85(2):601-6. DOI: 10.1210/jcem.85.2.6377
5. Rosenthal SM, Hulse JA, Kaplan SL, Grumbach MM. (1986). Exogenous growth hormone inhibits growth hormone-releasing factor-induced growth hormone secretion in normal men. J Clin Invest 77(1):176-83. DOI: 10.1172/JCI112273
6. Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL, Thorner MO. (1998). Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I: evidence for a suppressive action of free rather than bound IGF-I. J Clin Endocrinol Metab 83(8):2836-42. DOI: 10.1210/jcem.83.8.5040
7. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtsson BA. (1997). Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82(3):727-34. DOI: 10.1210/jcem.82.3.3809

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness